KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2016 - 2025)

Supernus Pharmaceuticals has reported Return on Capital Employed over the past 14 years, most recently at 5.67% for Q4 2025.

  • Quarterly Return on Capital Employed fell 1335.0% to 5.67% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.67% through Dec 2025, down 1335.0% year-over-year, with the annual reading at 5.81% for FY2025, 1373.0% down from the prior year.
  • Return on Capital Employed was 5.67% for Q4 2025 at Supernus Pharmaceuticals, down from 3.45% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 12.48% in Q1 2021 and troughed at 5.67% in Q4 2025.
  • The 5-year median for Return on Capital Employed is 5.14% (2022), against an average of 4.24%.
  • The largest YoY upside for Return on Capital Employed was 832bps in 2025 against a maximum downside of -1335bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 6.58% in 2021, then tumbled by -31bps to 4.57% in 2022, then crashed by -112bps to 0.53% in 2023, then soared by 1545bps to 7.68% in 2024, then crashed by -174bps to 5.67% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Return on Capital Employed are 5.67% (Q4 2025), 3.45% (Q3 2025), and 5.95% (Q2 2025).